The United States Patent and Trademark Office (USPTO) has granted a new U.S. patent for Palisade Bio’s (NASDAQ:PALI) lead investigational drug product, LB1148, for use in treating adhesions and postoperative ileus, which is a disruption of the normal propulsive ability of the intestine.
The patent will issue on Dec. 21, 2021 and confers broad coverage of the components in LB1148 for such treatments until 2037.
In a statement, Tom Hallam, Ph.D. and CEO of Palisade Bio said the new patent “specifically covers the use of LB1148 for the lead indications for which we plan to seek approval.”
He said the additional IP protection for LB1148 is a major milestone as the company advances its clinical pipeline and provides further data from a study of LB1148 for GI surgery patients.
“With this grant from the USPTO, we now have patents from three distinct families protecting LB1148 and its uses in the U.S., and we continue to pursue and obtain multi-family patent protection of LB1148 outside the United States to strengthen global IP protections,” he added.
In Phase 2 clinical trials, LB1148 demonstrated statistically significant improvements in accelerating the time to return of postoperative bowel function in gastrointestinal and cardiovascular surgery, and early observations also point to a reduction in adhesions following GI surgery.
